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Abstract
Introduction
haemophilia is an inherited bleeding disorder caused by a deficiency in one of the blood
coagulation factors. For people affected by severe haemophilia, the deficiency can cause
spontaneous internal bleeding. Most young people with severe haemophilia in the UK follow
a preventative treatment regimen (prophylaxis) consisting of several intravenous injections
of factor concentrate each week. There is good evidence that prophylaxis reduces bleeds
whilst also improving quality of life. However, levels of adherence among young people with
haemophilia reported in the existing literature vary widely and are predominately based on
estimations made by healthcare professionals and parents. Additionally, drivers of (non)
adherence among young people specifically have not been evidenced.
Aim
to assess self-reported adherence among young people with haemophilia, provide evidence
of psychosocial predictors of adherence, and to establish the associations between non-
adherence and number of bleeds and hospital visits.
Methods
91 participants were recruited during outpatient appointments in 13 haemophilia centres
across England and Wales, and invited to complete a questionnaire assessing self-reported
adherence (VERITAS-Pro), Haemophilia-related pain and impact of pain, Illness Percep-
tions, Beliefs about Medications, Self-efficacy, Outcome expectations, Positive and Nega-
tive Affect, and Social support. Number of hospital visits and bleeds during the previous six
months were collected from medical files.
Results
Of 78 participants with complete data, just 18% had scores indicating non-adherence. Psy-
chosocial predictors differed between intentional (skipping) and un-intentional (forgetting)
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non-adherence. Overall, however, better adherence was reported where participants per-
ceived the need for prophylaxis was greater than their concern over taking it as well as hav-
ing a positive expectancy of its effectiveness, good social support and a stronger emotional
reaction to having haemophilia.
Conclusion
The findings indicate that adherence is generally good, and that assessing illness and treat-
ment beliefs, social support and outcome expectations may play a valuable role in identify-
ing which individuals are at risk of non-adherence. Interventions aimed at improving
adherence should particularly consider improving social support, reducing patients’ con-
cerns about prophylaxis, increasing their belief in the necessity of prophylaxis, and increas-
ing positive outcome expectations.
Introduction
Haemophilia is an inherited bleeding disorder that occurs mostly in males and is caused by a
deficiency in one of the coagulation (blood clotting) factors in the blood. In the UK there are
currently approximately 5,900 people diagnosed with Haemophilia A and 1,200 Haemophilia
B [1].
Haemophilia A and B are classified as mild, moderate or severe based on the concentration
of factor measured via a blood test [2]. This study is concerned with patients with severe hae-
mophilia (approximately 1/3 of those with haemophilia) where, because they have a concentra-
tion of factor less than 1%, there is a greater risk of spontaneous joint and muscle bleeding, as
well as excessive bleeding after injuries, accidents and surgery.
Haemophilia is treated by replacing the deficient coagulation factor (factor VIII for haemo-
philia A, and factor IX for haemophilia B), in the blood through intravenous injections of fac-
tor concentrate. Treatment can be on-demand, where medication is used to treat a bleeding
episode; or preventative, where factor replacement treatment is used to increase the concentra-
tion of coagulation factor in the blood to prevent bleeding. Most young people with severe
haemophilia in the UK follow a preventative treatment regimen (prophylactic treatment or
prophylaxis). Patients with severe haemophilia A usually take three or four injections per week
on alternate days, whereas patients with severe haemophilia B usually take two or three injec-
tions per week. For each patient following a prophylactic treatment regimen for severe haemo-
philia, lifetime healthcare costs are estimated at £5.98 million for haemophilia A, and £2.47
million for haemophilia B [3].
United Kingdom Haemophilia Centre Doctors’ Organization (UKHCDO) guidelines[4]
recommend early implementation of prophylaxis for children with severe haemophilia, and
that adolescents and adults should be encouraged to continue regular prophylaxis at least
until they have reached physical maturity. Adherence to a prophylactic regimen is essential to
ensure that the full benefits (i.e. prevention of bleeding) are realised[5].
Reported levels of adherence to prophylaxis vary widely from 17%[6] to 59%[5]. A recent
systematic review by Schrijvers and colleagues [7] highlighted a lack of evidence in relation to
adherence to prophylaxis among young people with haemophilia, and that there is also a lack
of quality in much of the evidence published thus far. For example, adherence among young
people with haemophilia (YPH) is predominately based on estimations made by healthcare
Adherence to Prophylaxis among Young People with Haemophilia, Quantitative Study
PLOS ONE | DOI:10.1371/journal.pone.0169880 January 19, 2017 2 / 18
interested researchers (please contact s.b.van-
os@herts.ac.uk to request the data).
Funding: This work was supported by the Bayer
Haemophilia Caregiver award (http://www.bayer-
hemophilia-awards.com/archive/awards-2012/).
The research received external peer reviewed
funding from the Bayer Haemophilia Awards
Programme (Caregiver Award awarded to the first
author). The funder had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: Dr Hart, Dr Troop and Dr van
Os are currently involved in research funded by
Baxalta (part of Shire). Dr Hart has received
research support from Bayer (Early Career
Investigator Award) and Octapharma; travel
support from Octapharma and honoraria from
Baxter, Bayer, Novo Nordisk and Pfizer. Dr van Os
has received travel support and honoraria from
Bayer.
professionals and parents, rather than young people themselves [5, 8]. Due to the rarity of the
condition, sample sizes are often small. The existing literature includes just one study that
assessed adherence among people with severe haemophilia in the UK. In their single-centre
study Lllewellyn and colleagues[9] examined patient’s beliefs about their haemophilia (illness
perceptions[10] and beliefs about medicines[11]). They recruited 65 males with haemophilia
aged 12 and older, and found that greater beliefs in relation to illness identity (the label patients
use to describe the illness and symptomatology), expecting more severe consequences, and
greater perceived necessity of treatment were significantly associated with better adherence to
home treatment with clotting factor. However, despite the fact that younger people with hae-
mophilia are likely to have very different perceptions and experiences in relation to haemophi-
lia compared to older patients (thanks to enjoying the benefits of prophylaxis from an early
age), Llewellyn and colleagues did not look at younger and older age groups separately.
Non-adherence can be intentional, where a deliberate decision is made not to take treat-
ment, or unintentional, which is usually due to forgetting. It is possible that there are differ-
ent causes of these different types of adherence, but they have not been reliably separated in
the literature on adherence to prophylaxis. Therefore, this study aimed to assess adherence
reported by YPH themselves, using the VERITAS-Pro (Validated Hemophilia Regimen
Treatment Adherence Scale—Prophylaxis [12]) that assesses different dimensions of adher-
ence separately.
The existing adherence literature suggests that treatment adherence is multidimensional
and determined by a number of interacting factors. Different theories and research studies
emphasize different dimensions, but most agree that the key factors involved in adherence
relate to patient characteristics (e.g. demographics, illness perceptions, beliefs about medicines,
self-efficacy, etc.); clinical characteristics (e.g. complexity of regimen, severity of symptoms,
pain, etc.); social environment (social support, family dynamics, etc.); and the health care pro-
vider (e.g. relationship between patient and doctor, practicalities around medication collec-
tion/delivery, etc.).
Based on existing adherence research it was anticipated that:
1. there would be significant differences between adolescents and young adults in relation to
psychosocial correlates of adherence[13]
2. greater pain (and impact of this pain) would be associated with better adherence[6, 14]
3. illness perceptions, in particular higher perceptions of chronicity, consequences and treat-
ment control, would be predictive of higher adherence [9, 15]
4. beliefs about medicines, in particular perception of greater necessity of prophylactic treat-
ment, would be predictive of better adherence [9, 16–19].
5. patients with greater negative mood would have lower adherence scores[20–22].
Based on evidence that lower adherence results in worse disease outcomes [23, 24] it was
also anticipated that non-adherence to prophylaxis would be related to more bleeds and hospi-
tal visits.
Materials and Methods
Participants
Approximately 475 people in England and Wales met the inclusion criteria (diagnosed with
severe haemophilia, aged 12–25, following a prophylactic treatment regimen[1]). Eligible
patients were approached face-to-face during outpatient appointments in 13 haemophilia
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centres across England and Wales. Of the 125 invited patients, 109 agreed to participate,
although 18 did not return the questionnaire or later withdrew. Analysis was thus performed
on 91 participants, which at 19% of the total population is a substantial sample. Table 1 pres-
ents demographics for the total sample and adherence groups.
Procedure and measures
Ethical approval was obtained from South Yorks REC, Health Research Authority, National
Research Ethics Service (NRES, Ref: 13/YH/0143). Written consent was obtained before
patients completed the questionnaire. 80 participants completed a paper questionnaire in the
clinic and 11 participants completed an online version of the questionnaire at home. Number
of hospital visits and bleeds during the previous six months were collected from medical files.
The questionnaire, which was reviewed by a panel (of patients, haemophilia doctors, nurses
and a health psychologist) and then piloted with patients to ensure validity, included questions
assessing self-reported adherence and a number of cognitive, social and emotional factors that
previous research has suggested may relate to adherence.
Table 1. Demographics for the entire sample and adherence groups.
Total sample
(n = 91)
Adherent
(n = 64)
Non-adherent
(n = 14)
Age
Mean (SD) 18.99 (4.11) 19.00 (4.22) 18.94 (3.75)
Min/max 12/25 12/25 13/24
Education/Work
School 30 (33%) 19 (29.7%) 3 (21.4%)
College/university 19 (20.9%) 15 (23.4%) 3 (21.4%)
Other full-time education 1 (1.1%) 0 1 (7.1%)
Part-time work 8 (8.8%) 7 (10.9%) 0
Full-time work 23 (25.3%) 16 (25.0%) 5 (35.7%)
Don’t work 6 (6.6%) 4 (6.3%) 2 (14.3%)
Other 2 (2.2%) 2 (3.1%) 0
Missing 2 (2.2%) 1 (1.63%) 0
Living arrangements
I live with my parents 71 (78%) 49 (76.6%) 11 (78.6%)
I live independently alone 4 (4.4%) 2 (3.1%) 2 (14.3%)
I live independently with others 15 (16.5%) 13 (20.3) 1 (7.1%)
Missing 1 (1.1%) 0 0
Responsibility for prophylaxis
Someone else does injections for me 8 (8.8%) 7 (10.9%) 0
They are done by someone else, and I help 10 (11%) 6 (9.4%) 1 (7.1%)
They are mostly done by me with help from someone else 8 (8.8%) 6 (9.4%) 0
I do them entirely myself 64 (70.3%) 45 (70.3%) 12 (85.8%)
Missing 1 (1.1%) 0 1 (7.1%)
Siblings with Haemophilia
Yes 18 (19.8%) 14 (21.9%) 4 (28.6%)
No 71 (78%) 50 (78.1%) 10 (71.4%)
Missing 2 (2.2%) 0 0
Adherence scores were only available for 78 patients. There were no significant differences between adherers and non-adherers in relation to any of the
demographics (highest chi-square F = 4.39, lowest p value = 0.11).
doi:10.1371/journal.pone.0169880.t001
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Adherence
The Validated Hemophilia Regimen Treatment Adherence Scale-Prophylaxis (VERITAS-Pro)
[25] is a 24-item measure of self-reported adherence to prophylaxis among people with hae-
mophilia. The scale consists of six sub-scales which examine the extent to which participants
take their injections at the recommended time (Timing), use the recommended dose (Dosing),
plan ahead to ensure they have enough supplies (Planning), remember to take their injections
(Remembering), skip injections (Skipping) and communicate with the haemophilia centre
appropriately (Communicating). The scale was revised slightly to make it appropriate for UK
patients, and was then reviewed and tested by a panel of patients, haemophilia doctors, nurses
and a health psychologist. The panel recommended that the Dosing subscale should not be
included because many UK patients follow a more flexible regimen that is tailored around
their physical activity. Therefore patients who do not keep to an agreed treatment schedule are
not necessarily non-adherent. Scores on each VERITAS-Pro subscale range from 4 to 20, with
higher scores indicating poorer adherence. Participants were dichotomised into Adherent and
Non-adherent using the cut-off proposed by the original validation studies[25, 26].
Illness perceptions
The Brief Illness Perception Questionnaire[27] uses single-item scales to assess each of eight
illness perceptions on a 0–10 response scale. It comprises six cognitive representations of ill-
ness perception: Consequences (expected negative effects and outcome of the illness), Timeline
(how long the patient expects the illness will last), Personal control (patients’ ability to influence
symptoms), Treatment control (extent to which treatment reduces symptoms), Identity (the
label patients use to describe the illness and the symptomatology), and Coherence (understand-
ing of the illness). There are two items on emotional representations: Concern (about the ill-
ness), and Emotional responses (negative reactions to the illness such as fear, anger or distress).
A ninth illness perception, Cause, is included in some studies and asks participants to list the
three most important causes of their health condition. However this item was not included in
this study following feedback from the panel (of patients, haemophilia doctors, nurses and a
health psychologist) and the pilot with patients, as they suggested this question did not make
sense (as haemophilia is inherited genetic disorder that is often diagnosed when people are
very young).
Beliefs about medicines
The Beliefs about Medicines Questionnaire[16] consists of two sections; beliefs about medi-
cines in general and beliefs about the specific medication prescribed for a given condition. For
the purpose of this study only the BMQ Specific was included, which consists of two subscales;
Concerns and Necessity. The Concerns subscale included five questions referring to concerns
patients might have about prophylaxis. The Necessity subscale included five questions related
to patients’ perceptions about the need to take prophylaxis. Questions were scored on a
5-point Likert scale with higher scores indicating more concerns and stronger belief in the
necessity of prophylaxis. The Necessity-Concern differential was calculated (subtracting scores
on Concern from scores on Necessity) as an indicator of the degree to which perceptions of
necessity outweigh the concerns.
Self-efficacy
In accordance with Bandura’s[28] situation-specific behaviour-based model, two self-efficacy
scales were used. The first scale assessed self-efficacy in relation to haemophilia in general and
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the second asked about prophylaxis specifically. New scales were devised using Bandura’s
guide for constructing self-efficacy scales[29]. The content of the scales was informed by previ-
ous research looking at adherence among young people with type I diabetes[30, 31], and a
pilot study that identified key haemophilia self-management behaviours and difficulties that
young people experience in relation to prophylaxis. The two scales can be obtained from the
authors on request.
The haemophilia-related self-efficacy scale consisted of three subscales: Communication
about haemophilia (three items); Taking prophylaxis (seven items); and Your health, managing
health and preventing/dealing with haemophilia-related issues (two items). To assess prophy-
laxis-related self-efficacy participants were invited to rate how confident they were that they
could take their prophylaxis in 10 situations that were identified as challenging by the pilot
study (e.g. when I am tired, when I’m busy, etc.). Each item was scored on a 0–10 response
scale with higher scores indicating greater self-efficacy.
Outcome expectations
The Outcome Expectations scale was developed in the same way as the self-efficacy scales and
can also be obtained from the authors on request. Each of the 10 items was a potential answer
to the question: ‘If I always did everything I am supposed to do to manage my haemophilia, it
would. . ...‘. Patients were asked to rate how much they agreed with each potential answer
using a 0–10 scale. Five of the answers represented positive outcome expectations (e.g. keep
me healthy), and five represented negative outcome expectations (e.g. be too time consuming).
Higher scores indicated a greater expectation.
Positive and Negative Affect Schedule (PANAS)
The Positive and Negative Affect schedule [32] is a valid and reliable self-report measure of
both negative and positive mood states. It consists of two 10-item mood scales asking partici-
pants to rate specific feelings and emotions associated with positive affect (e.g. enthusiasm)
and negative affect (e.g. being afraid) experienced during a given time. Participants were
invited to rate the extent to which they experienced each emotion during the past week. Indi-
viduals responded to each item on the following scale: (1) very slightly or not at all, (2) a little,
(3) moderately, (4) quite a bit, and (5) very much.
Social support
Based on research with young people with diabetes [30, 33–35] and research in haemophilia
[36, 37], the most important potential sources of social support in relation to prophylaxis were
identified. This resulted in an 8-item questionnaire with a layout that was based on the Diabe-
tes Family Behavior Checklist [38]. Participants were invited to rate how often they receive
support (from anyone) in relation to each of the items using a 6-point scale ranging from 0 to
5 (never, less than twice a month, twice a month, once a week, several times a week, at least
once a day). They were then asked to indicate their satisfaction with this support using a
5-point scale ranging from -1 to 3 (Unhelpful or NOT supportive, Neutral, A little helpful/sup-
portive, Helpful/Supportive, Very supportive). The overall social support score was obtained
by multiplying the frequency score by the satisfaction score with higher scores indicating
greater social support.
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Results
Data screening
Missing data was at an acceptable level and mostly missing at random. However, there were
larger numbers of missing responses for some of the VERITAS-Pro subscales, which were sys-
tematically missing due to patients answering ‘not applicable’. Therefore analyses were carried
out using listwise deletion for the VERITAS-Pro data and means imputation for the other
(randomly missing) data. Listwise deletion resulted in different numbers of participants being
included in different analyses; please see relevant tables for precise numbers.
In order not to violate the assumption of normality, which is necessary for many of the sta-
tistical analyses, log transformations were performed for positively skewed variables and
square transformations were performed for negatively skewed data.
Adherence to prophylaxis in the sample
To test potential differences between adherent and non-adherent patients the sample was
dichotomised into two groups (adherent and non-adherent). The VERITAS-Pro [25] has
cut-off scores for each sub-scale and, since in the present study the Dosing subscale was not
included, the cut-off for the total score (overall adherence) was calculated excluding this sub-
scale, giving a cut-off where score 51 indicate non-adherence. On this basis overall adher-
ence was good (see Table 2); of 78 participants with complete data just 18% had a score that
indicated that they were non-adherent.
Only four patients (4%) had Skipping scores 11, indicating intentional non-adherence,
and only 19 patients (24%) had Remembering scores 11, indicating unintentional non-
adherence. Of these, only three (4%) were both intentionally and unintentionally non-adher-
ent (i.e. only one patient reported intentional non-adherence without also reporting uninten-
tional non-adherence).
Table 2. Clinical outcomes of adherent and non-adherent patients.
Adherent (n = 64) Non-adherent (n = 14)
N Mean SD Min Max Skew Kurtosis N Mean SD Min Max Skew Kurtosis
Age 65 19.34 4.01 12 25 -0.15 -1.27 14 19.50 3.44 14 24 -0.27 -1.07
Self-reported adherence (VERITAS-Pro)
Log Timing** 65 6.14 1.41 4 12 0.06 -1.23 14 12.06 1.32 7 17 -0.61 -0.61
Log Planning** 65 6.22 1.49 4 16 0.47 -0.79 14 10.16 1.39 6 16 -0.14 -0.95
Remembering 65 7.28 2.27 4 11 0.01 -1.15 14 12.38 2.59 8 17 -0.05 -0.37
Log Skipping** 65 5.01 1.35 4 15 -0.08 -1.31 14 7.06 1.56 4 14 -0.08 -1.31
Communicating** 65 12.07 4.14 4 20 -0.13 -0.67 14 15.26 2.65 9 18 -1.17 1.02
Sum** 65 37.87 7.24 20 51 -0.17 -0.35 14 58.50 5.60 53 73 1.80 2.88
Clinical information
Pain severity┬ 62 2.94 1.41 0 6 0.30 -0.87 13 3.15 1.73 0 6 0.07 -1.42
Impact of pain┬ 64 2.16 1.25 0 5 1.05 0.08 13 2.46 1.71 0 6 0.66 -1.14
Log Total bleeds**┬┬ 60 3.34 2.70 0 26 0.35 -0.88 14 1.41 1.79 0 4 1.54 1.49
Log Hospital visits*┬┬ 49 2.82 2.62 0 19 0.46 -1.12 11 1.95 1.95 0 8 0.85 0.47
Where transformation has been undertaken the geometric mean and SD are shown. Difference between adherence and non-adherent (*p<0.05,
**p<0.001) as measured by independent t-test.
┬during previous 4 weeks,
┬┬during previous 6 months.
doi:10.1371/journal.pone.0169880.t002
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The Communicating sub-scale was the only sub-scale on which a majority of patients (81%)
had scores above the cut-off (10) indicating non-adherence. This is likely because some of
the Communicating questions appear to lack content validity, as they assume that patients have
to contact the haemophilia team to agree treatment adjustments (e.g. to provide cover for
physical activities). However, many UK patients make these adjustments based on parameters
they have agreed with their haemophilia clinician in advance, without the need to contact their
haemophilia team for each adjustment.
Adherence and clinical outcomes
Non-adherent patients had significantly fewer bleeds (mean difference -2.71, t(74) = -3.593,
p = 0.001) and hospital visits (mean difference -0.507, t(64) = -2.235, p = 0.034) than adherent
patients (see Table 2). There were no significant differences in relation to severity of pain and
impact of this pain.
Psychosocial factors and adherence
Table 3 presents correlations between overall adherence and psychosocial factors. Greater
adherence is associated with stronger beliefs in the necessity of prophylaxis, stronger emo-
tional responses to haemophilia (such as fear, anger or distress), more positive outcome expec-
tations, more social support, and being more satisfied with this support. Poorer adherence is
associated with greater concerns about prophylactic treatment.
When the sample was dichotomised into adherent/non-adherent (Table 4), non-adherent
patients had significantly lower belief in the necessity of prophylaxis (mean difference -2.494, t
(89) = -2.568, p = 0.12), lower necessity/concern differentials (mean difference -4.219, t(89) =
3.348, p = 0.001), lower prophylaxis-related self-efficacy mean difference -10.12, t(89) = -2.656,
p = 0.009), and less social support (mean difference -2.83, t(89) = -2.824, p = 0.006) than
adherent patients. Non-adherent patients also had stronger illness perceptions in relation to
timeline (mean difference 0.3, t(89) = 2.194, p = 0.033), indicating that they believe the dura-
tion of haemophilia to be longer (i.e. explicit recognition of it being a true life long condition).
Ability of psychosocial factors to predict adherence
To further test the association between overall adherence and psychosocial factors, multiple
linear regression analyses were carried out. To start with all psychosocial factors were entered
using the fixed enter method, which resulted in a model that accounted for 48.8% of the varia-
tion in overall adherence (df = 19, p = .001). In the model better overall (sum) adherence was
associated with fewer concerns about treatment, greater belief in the necessity of treatment,
greater emotional responses to haemophilia and greater social support (frequency  satisfac-
tion). As the majority of factors were not significantly associated with adherence a second
model was run in which the factors were entered using the forward stepwise method, resulting
in a model that only includes significant predictors. In this model (Table 5), which accounted
for 37.5% of the variance in adherence, a greater necessity/concern differential, greater social
support (frequency × satisfaction), greater emotional responses to haemophilia and more posi-
tive outcome expectations were associated with better adherence.
Skipping and forgetting
To examine the difference between intentional and unintentional adherence, and because
there were some questions about the validity of the Communicating subscale (possibly affecting
the overall adherence scores), separate regression analyses were carried out for the Skipping
Adherence to Prophylaxis among Young People with Haemophilia, Quantitative Study
PLOS ONE | DOI:10.1371/journal.pone.0169880 January 19, 2017 8 / 18
and Remembering subscales. The results of these linear regression analyses are presented in
Table 5. The Remembering model accounted for 44.5% of the variance (p = 0.003), with only
fewer concerns about treatment and lower perception of treatment control (the extent to
which a patient believes their treatment can control symptomatology) showing a significant
association with better Remembering.
The Skipping model accounted for 41.5% of the variance (p = 0.008), with fewer concerns
about treatment, fewer negative outcome expectations (negative outcomes of taking treat-
ment), lower negative affect, lower coherence (overall comprehension of haemophilia), and
greater emotional responses to haemophilia (such as fear, anger or distress) showing a signifi-
cant association with less skipping.
Differences between adolescents and young adults
Differences between adolescents (aged 12–17) and young adults (aged 18–25) are presented in
Table 6. Young adults had lower adherence scores on all adherence subscales, although none
of these was statistically significant. They also did not differ significantly in number of bleeds
or visits to the haemophilia centre.
Table 3. Pearson’s correlation between adherence subscales and psychosocial factors.
Log Timing Log Planning Remembering Log Skipper Communicating Adherence Sum
Beliefs about Medicines (BMQ)
BMQ Concern .248* .124 .290** .359** -.033 .262*
BMQ necessity -.325** -.124 -.090 -.057 -.148 -.249*
Differential -.414** -.178 -.265* -.286* -.090 -.366**
Self-regulatory model (IPQ)
Consequences -.081 .125 -.038 .046 -.092 -.019
Squared Timeline -.021 .083 .196 -.082 .015 .086
Squared Personal Control .017 .119 .132 .085 .146 .161
Squared Treatment Control .120 .029 .190 -.087 -.084 .057
Identity -.016 .208 .005 .053 -.096 .047
Concerns .023 -.070 .025 .081 -.244* -.098
Coherence -.125 -.229* -.058 .181 -.320** -.206
Emotional representations -.112 -.126 -.061 .025 -.348** -.223*
Outcome expectations and Self-efficacy
Positive outcome expectations -.145 -.456** -.285* -.183 -.124 -.363**
Negative outcome expectations .148 -.008 .157 .293** -.181 .087
Squared Haemophilia-related Self efficacy -.092 -.147 .008 -.147 .018 -.107
Squared Prophylaxis-related Self efficacy -.254* -.199 -.154 -.198 .093 -.188
Mood (PANAS)
Positive affect -.075 -.159 -.090 -.025 -.045 -.128
Log Negative affect -.057 -.004 .028 .191 -.061 .007
Social support
Frequency -.123 -.160 -.191 -.048 -.400** -.297**
Satisfaction -.153 -.105 -.232* -.165 -.334** -.301**
Frequency*Satisfaction -.140 -.139 -.145 -.152 -.406** -.305**
*p<0.05
**p<0.001
┬ during previous 4 weeks
┬┬ during previous 6 months. Listwise N = 79.
doi:10.1371/journal.pone.0169880.t003
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In relation to psychosocial factors of adherence, young adults had greater belief in the
necessity of treatment (mean difference -1.967, t(89) = -2.528, p = 0.013), and had greater
necessity/concern differential scores (mean difference -2.488, t(89) = -2.398, p = 0.019) indi-
cating that their belief in the necessity of treatment outweighs their concerns about treatment.
Young adults also perceived themselves to have more personal control over their symptoms
(mean difference -1.202, t(89) = -2.374, p = 0.02), and had greater self-efficacy scores both in
relation to haemophilia in general (mean difference -6.720, t(89) = -2.270, p = 0.026) and pro-
phylaxis specifically (mean difference -8.431, t(89) = -2.112, p = 0.037). Young adults also had
fewer negative outcome expectations (mean difference 4.820, BCa 95% CI [1.128, 8.513], t(89)
= 2.594, p = 0.011), and reported to receive significantly less social support than adolescents
(mean difference 9.273, t(89) = 4.551, p = 0.0001), but their satisfaction with the social support
they receive did not differ significantly.
Discussion
This study examined levels of self-reported adherence to prophylaxis in 91 adolescents and
young adults with severe haemophilia, in particular differentiating between intentional and
Table 4. Psychosocial factors of adherent and non-adherent patients.
Adherent (n = 64) Non-adherent (n = 14)
N Mean SD Min Max Skew Kurtosis N Mean SD Min Max Skew Kurtosis
Beliefs about medicines
Concern 64 10.12 3.65 5 18 0.23 -1.05 14 11.71 2.70 7 16 -0.08 -1.07
Necessity* 64 20.26 3.68 8 25 -1.09 1.29 14 17.36 4.40 9 25 -0.03 -0.53
Necessity/Concern differential** 64 10.14 5.08 -7 20 -0.65 1.01 14 5.64 4.27 -3 11 -0.54 -0.35
Self-regulatory Model (Brief IPQ)
Consequences 63 6.05 3.07 0 10 -0.40 -0.84 14 5.36 3.57 0 10 -0.47 -1.15
Squared Timeline* 63 9.61 4.12 5 10 -2.34 5.06 14 9.87 3.10 8 10 -3.74 14.00
Squared Personal Control 63 7.11 5.35 0 10 -0.12 -0.67 14 7.58 4.73 5 10 0.01 -0.30
Squared Treatment Control 63 8.94 4.89 3 10 -1.06 0.37 14 9.15 4.58 7 10 -0.69 -1.36
Identity 63 5.25 2.67 0 10 -0.03 -0.84 14 5.43 2.31 0 8 -1.05 1.11
Concerns 63 4.35 3.00 0 10 0.50 -0.87 14 4.14 3.13 0 10 0.09 -0.83
Coherence 63 8.59 1.50 5 10 -0.92 -0.15 14 8.36 1.55 6 10 -0.56 -1.17
Emotional Representations 62 4.10 3.14 0 10 0.21 -1.08 14 3.64 2.59 0 7 -0.32 -1.38
Self-efficacy and Outcome expectations
Squared Haemophilia-related Self-efficacy 65 106.39 52.04 54 120 -0.12 -1.25 14 105.55 44.80 90 118 -0.12 -1.25
Squared Prophylaxis-related Self-efficacy* 65 85.99 52.28 27 100 -0.99 0.04 14 76.38 52.28 31 100 -0.09 -0.70
Positive Outcome expectations 65 37.49 11.45 6 60 -0.30 0.21 14 32.50 10.54 10 53 0.08 1.21
Negative Outcome expectations 64 14.34 9.24 4 40 0.69 -0.30 14 16.93 8.52 5 33 0.46 -0.88
Mood (PANAS)
Positive affect 63 32.90 9.84 10 50 -0.72 0.20 14 28.73 7.73 12 38 -0.72 -0.05
Log Negative affect 63 10.83 1.47 7 32 0.72 -0.13 14 11.26 1.49 7 21 0.21 -1.33
Social Support
Frequency 64 18.36 11.21 0 40 0.35 -0.99 14 15.50 8.37 2 30 0.25 -1.08
Satisfaction 59 10.59 7.68 -7 24 -0.11 -0.85 13 8.65 5.89 -1 19 -0.14 -0.62
FrequencyxSatisfaction* 54 30.74 29.47 -7 120 0.89 0.19 11 27.91 21.58 -3 64 0.71 -0.65
Difference between adherence and non-adherent (* p<0.05, **p<0.001) as measured by independent t-test.
doi:10.1371/journal.pone.0169880.t004
Adherence to Prophylaxis among Young People with Haemophilia, Quantitative Study
PLOS ONE | DOI:10.1371/journal.pone.0169880 January 19, 2017 10 / 18
unintentional non-adherence. In addition, factors associated with these types of adherence
were examined.
The findings of this study suggest that overall adherence among young people with haemo-
philia (YPH) is good. This is in line with some studies that looked at adherence to prophylaxis
[14], but exceeds adherence levels reported by a previous UK study [9] and several other stud-
ies conducted in Europe and the US [5, 8, 39, 40]. Differences in adherence levels reported by
various studies may be due to the diverse methods used to assess adherence, and variations in
the way haemophilia is treated in different countries, or even within countries. Differences
between countries are often due to costs, and therefore the way that haemophilia care is funded
for individual patients plays an important role (e.g. insurance, state funded, or privately
funded). Indeed, several studies from the U.S highlight cost of treatment as one of the main
barriers to adherence [5, 37]. Because of the healthcare system in the UK, which funds haemo-
philia treatment for all patients, levels of adherence in the UK are less likely to be associated
with concerns about costs.
Table 5. Linear regression models of predictors of adherence sum, skipping, and forgetting.
b SE B β P ΔR2
Predicting variables Adherence Sum
Step 1 BMQ Necessity/Concern differential -0.744 0.216 -0.366 0.001 .134**
Step 2 BMQ Necessity/Concern differential -0.785 0.204 -0.386 <0.001 .107*
Social support frequency*satisfaction -0.136 0.041 -0.328 0.002
Step 3 BMQ Necessity/Concern differential -0.883 0.196 -0.434 <0.001 .084*
Social support frequency*satisfaction -0.137 0.039 -0.331 0.001
IPQ Emotional responses -1.041 0.341 -0.294 0.003
Step 4 BMQ Necessity/Concern differential -0.757 0.197 -0.372 <0.001 .049*
Social support frequency*satisfaction -0.125 0.038 -0.302 0.002
IPQ Emotional responses -0.988 0.331 -0.279 0.004
Positive outcome expectations -0.213 0.089 -0.231 0.019
Predicting variables Skipping
Step 1 BMQ Concern 0.031 0.01 0.321 0.003 .103*
Step 2 BMQ Concern 0.042 0.01 0.428 <0.001 .096*
IPQ Coherence 0.077 0.025 0.327 0.003
Step 3 BMQ Concern 0.042 0.01 0.436 <0.001 .043*
IPQ Coherence 0.085 0.025 0.361 0.001
Social support frequency*satisfaction -0.003 0.001 -0.209 0.041
Predicting variables Forgetting
Step 1 BMQ Concern 0.274 0.092 0.316 <0.001 .100*
Step 2 BMQ Concern 0.392 0.093 0.453 <0.001 .119*
Square Treatment control 0.05 0.014 0.371 0.001
Step 3 BMQ Concern 0.368 0.09 0.425 <0.001 .069*
Square Treatment control 0.056 0.014 0.413 <0.001
Social support satisfaction -0.117 0.043 -0.27 0.008
Step 4 BMQ Concern 0.339 0.089 0.391 <0.001 .042*
Square Treatment control 0.057 0.014 0.426 <0.001
Social support satisfaction -0.101 0.042 -0.234 0.019
Positive outcome expectations -0.058 0.027 -0.212 0.033
*p<0.05,
**p<0.001
doi:10.1371/journal.pone.0169880.t005
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Unintentional and intentional non-adherence
When non-adherence was split into intentional (skipping) and unintentional (forgetting) it
appeared that non-adherence was most likely due to forgetting. Because there were just four
Table 6. Adherence and psychosocial scores for the total sample, adolescents, and young adults.
Adolescents (n = 41) Young adults (n = 50)
Mean SD Min Max Skew Kurtosis Mean SD Min Max Skew Kurtosis
Age 15.00 1.88 12 18 0.00 -1.09 22.26 1.97 19 25 -0.09 -1.17
Self-reported adherence (VERITAS-Pro)
Log Timing 6.75 1.59 4 16 0.39 -1.02 7.05 1.47 4 17 0.39 -1.02
Log Planning 6.54 1.54 4 16 0.44 -0.95 6.75 1.53 4 16 0.32 -0.86
Remembering 8.05 3.28 4 14 0.41 -1.04 8.40 2.92 4 17 0.76 1.14
Log skipping 5.24 1.38 4 12 1.031 -0.004 5.37 1.45 4 15 1.17 0.60
Communicating 11.53 4.16 4 20 0.08 -0.90 12.95 4.07 4 19 -0.50 -0.31
Sum 40.38 12.26 23 73 0.88 0.44 42.35 9.16 20 60 0.21 -0.15
Clinical information
Pain severity 2.73 5.58 0 6 0.26 -0.99 3.08 1.41 0 6 0.31 -0.87
Impact of pain 2.23 1.33 0 5 0.98 -0.20 2.12 1.39 0 5 1.02 -0.35
Log spontaneous bleeds 2.33 2.91 0 26 1.24 0.68 3.01 2.51 0 13 0.00 -1.22
Log Traumatic bleeds 2.09 2.19 0 12 0.61 1.84 1.55 1.84 0 8 1.44 2.07
Log Hospital visits 3.38 2.93 0 19 0.19 -1.52 2.27 2.28 0 17 0.70 -0.56
Beliefs about medicines (BMQ)
Concern 11.08 3.36 5 18 0.22 -0.75 10.54 3.98 5 18 0.11 -1.29
Necessity* 18.66 4.41 8 24 -0.65 -0.22 20.71 3.17 13 25 -0.60 -0.24
Necessity/Concern differential* 7.58 5.18 -7 15 -0.69 0.77 10.18 4.86 -1 20 -0.13 -0.14
Self-regulatory Model (Brief IPQ)
Consequences 6.16 3.06 0 10 -0.56 -0.67 5.68 3.20 0 10 -0.21 -1.15
Squared Timeline 9.53 4.22 5 10 -2.13 4.45 9.74 3.77 6 10 -2.84 7.52
Squared Personal Control* 6.54 5.03 0 9 -0.38 -0.82 7.54 5.26 0 10 -0.38 -0.82
Squared Treatment Control 8.98 4.75 5 10 -0.91 -0.07 8.98 4.90 3 10 -1.12 0.60
Identity 5.78 2.58 0 10 -0.55 -0.27 5.20 2.54 0 10 -0.09 -0.80
Concerns 4.71 3.01 0 10 0.20 -1.07 4.64 3.12 0 10 0.09 -1.01
Coherence 8.53 1.50 5 10 -0.79 -0.53 8.56 1.53 5 10 -0.82 -0.45
Emotional Representations 4.65 3.07 0 10 0.02 -0.92 3.70 3.09 0 10 0.26 -1.20
Self-efficacy and Outcome expectations
Squared Haemophilia-related Self-efficacy* 100.96 52.18 73 118 -0.29 -1.07 107.62 51.79 54 120 -1.30 1.53
Squared Prophylaxis-related Self-efficacy* 79.15 53.70 27 100 -0.44 -1.01 86.49 50.48 35 100 -0.90 -0.17
Positive Outcome expectations 38.25 11.37 6 60 -0.54 0.17 35.91 10.45 8 60 -0.09 0.97
Negative Outcome expectations* 18.40 9.73 4 40 0.26 -0.89 13.47 8.19 4 29 0.45 -1.09
Mood (PANAS)
Positive affect 30.96 9.88 11 49 -0.50 -0.27 31.69 10.36 10 50 -0.50 -0.36
Log Negative affect 9.94 1.42 7 23 0.93 -0.14 11.59 1.50 7 32 0.40 -0.60
Social Support
Frequency 24.15 88.78 10 40 0.14 -1.19 14.75 10.39 0 40 0.78 -0.24
Satisfaction* 12.37 7.66 -2 24 -0.19 -1.02 8.99 7.49 -7 24 0.16 -0.60
FrequencyxSatisfaction** 38.69 27.79 -3 96 0.40 -0.86 26.75 29.76 -7 120 1.29 1.29
Where transformation has been undertaken the geometric mean and SD are shown. Difference between adolescents and young adults (* p<0.05,
**p<0.001) as measured by independent t-test.
doi:10.1371/journal.pone.0169880.t006
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participants who admitted to skipping treatments (of which three also admitted to forgetting)
it is impossible to comment on potential differences between intentional and unintentional
non-adherence. It is unclear whether non-adherence is due to patients’ busy lifestyles or that
they find it easier to admit to forgetting rather than skipping (since they may receive a more
understanding response to forgetting, rather than being ‘told off’ by loved ones or the haemo-
philia team for intentionally skipping).
Differences between adolescents and young adults
Although there were significant differences in psychosocial factors between adolescents and
young adults, they did not differ on adherence. This is likely because, of the factors that signifi-
cantly contributed to the variation in adherence in the regression analyses, only the necessity/
concern differential was significantly different between age groups.
Association between adherence and clinical outcomes
Contrary to the anticipated relationship between non-adherence and greater frequency of
bleeds and hospital visits, the findings indicate that adherers experience more bleeds and hos-
pital visits than non-adherers. There are several potential explanations for this:
1. We collated the number of bleeds and hospital visits that patients had during the last 6
months, whereas we assessed patients’ adherence during the last month. Therefore it could
be that patients who experienced frequent and/or severe bleeds more than one month ago
were motivated to improve their adherence in order to reduce the risk of bleeding, resulting
in better adherence scores.
2. More adherent patients may be more attentive to bleeding episodes and symptoms of
bleeds, whereas less adherent patients may be more relaxed and less likely to interpret
symptoms as bleeds. Non-adherent patients may also be less likely to report bleeds to the
haemophilia team through an online, patient reported treatment diary (Haemtrack) or by
calling the haemophilia centre. Non-adherent patients may therefore experience more
bleeds than are reported.
3. More adherent patients may be more confident in the protection afforded by their prophy-
laxis, and therefore more likely to engage in physical activity. This in turn may increase
their risk of bleeding (due to activity-related injury or increased pressure on joints and
muscles), compared to non-adherent people who may engage less in physical activity.
4. 10–15% of patients with severe haemophilia have a mild bleeding phenotype [41] which
means that they are less likely to suffer bleeds and may therefore ‘get away’ with suboptimal
adherence to prophylaxis.
To better understand the association between adherence and clinical outcomes, future
research should assess self-reported bleeds and hospital visits as well as data collated from
medical notes. This will allow validation of clinical data and offer the opportunity to analyse
the relationship between adherence and clinical outcomes in more detail.
Psychosocial predictors of adherence
Correlation analyses suggest that greater belief in the necessity of prophylaxis, fewer concerns
about prophylaxis, stronger emotional responses to haemophilia (such as fear, anger or dis-
tress), more positive outcome expectations, and more frequent social support and satisfaction
with this support are associated with better adherence.
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Comparison of adherers and non-adherers indicates that adherers have greater belief in the
necessity of prophylaxis, greater necessity/concern differentials, greater prophylaxis-related
self-efficacy, and greater social support than non-adherers. Non-adherent patients had greater
illness perceptions in relation to the timeline (duration) of haemophilia (i.e. believed correctly
that it is a chronic rather than time-limited condition).
In the regression analyses, a greater necessity/concern differential predicted better overall
adherence. This indicates that when the outcome of the cost-benefit analysis that patients
carry out in relation to taking their treatment is positive, they are more likely to adhere. Other
predictors of better adherence were greater social support, more negative emotional responses
to haemophilia (such as fear or anxiety), and greater positive outcome expectations.
Greater concerns about prophylaxis were predictive of both skipping and forgetting. This is
likely to include concerns about the long-term effects of prophylaxis, the extent to which pro-
phylaxis disrupts life, worries about not understanding treatment or becoming too dependent
on prophylaxis.
In addition to greater concerns, skipping was also associated with lower social support (fre-
quency x satisfaction) and interestingly with greater coherence (overall understanding of hae-
mophilia). Forgetting was also associated with lower satisfaction with social support, lower
positive outcome expectations and greater perceptions of treatment control. It is unclear why
people who perceive themselves to have a better understanding of their haemophilia are also
more likely to skip, and why people who have greater perceptions of treatment control, are
more likely to forget prophylaxis.
These results are partly in line with the findings of a previous UK study by Llewellyn and
colleagues [9], who found significant associations between better adherence to prophylaxis
and greater perceptions of treatment necessity, illness identity (symptomatology), and illness
consequences.
Strengths and limitations
There are a number of limitations that should be acknowledged. For example, the main out-
come measure of this study, the VERITAS-Pro, is a relatively new scale and no previous litera-
ture exists using this scale in the UK. Due to limited resources it was not possible to validate
the VERITAS-Pro. However, the results of this study suggest that there may be some issues
around validity of the VERITAS-Pro, as the majority of missing data for this scale was due
patients answering ‘not applicable’. This appeared to be particularly the case for questions that
assume that patients take treatment according to a pre-agreed schedule that does not allow for
flexibility. This reflects the fact that the VERITAS-Pro was constructed and validated in the
US, and perhaps does not reflect the more flexible and personalised way in which many YPH
in the UK manage their treatment. Although the internal reliability of the Brief Illness Percep-
tions Questionnaire was good, it may be considered a limitation that this short-form version
was used instead of the longer IPQ-R[42]. However, utilising short form scales allowed this
study to include a wider range of measures. Another limitation that should be highlighted is
the fact that clinical outcome data (bleeds and hospital visits) were collated by nurses relying
on individual patient medical files. This method is prone to inaccuracies and missing data,
therefore the unexpected association between adherence and more frequent bleeds and hospi-
tal visits could be due to errors and missing data. It would be advisable to validate clinical data
by including self-report measures of bleeds and hospital visits in any future studies.
However, the study also has a number of strengths. The existing literature is very limited in
terms of the number as well as the quality of studies published. A strength of this study is that
it is a nationwide study (recruiting participants from 13 hospitals across England and Wales).
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It also has a relatively large sample for studies of this type with 19% of the total population who
met the inclusion criteria participating. It also has a specific focus on young people rather than
including patients of all age groups. This is important since people in this group are likely to
have been using prophylaxis all or most of their lives. Lastly, rather than asking parents or
healthcare professionals to estimate adherence, this study asked young people directly to com-
plete the questionnaire themselves.
Implications
Although the current study did not replicate the exact associations found by Llewellyn and col-
leagues, the findings confirm that assessing illness and treatment beliefs may play a valuable
role in identifying which individuals are least likely to adhere to prophylaxis.
It appears important that patients receive sufficient and appropriate social support in order
to stay on track with their treatment. In addition, the findings indicate that it may be beneficial
to reduce potential concerns about prophylaxis, and to assess whether patients understand
their treatment sufficiently well and the role they themselves play in its efficacy. Interestingly,
the findings also suggest that emotional responses in relation to haemophilia, such as fear,
anger or distress, may contribute to better adherence. However, in a busy clinic it may not
always be easy to tease out whether someone is simply concerned about their prophylactic
treatment, or whether they are experiencing negative emotions that could actually contribute
towards better adherence.
The association between better adherence and worse clinical outcomes could suggest that
low adherence may not necessarily always be an issue that needs to be addressed by the haemo-
philia team. In practice this could mean that perhaps their attention should be focused on
patients who present with bleeds and associated issues, rather than any patient with sub-opti-
mal adherence. However, before drawing any conclusions in this direction it would be useful
to replicate these findings, ensuring that clinical data are validated with patient-reported data
(the number of bleeds and hospital visits).
Conclusion
In conclusion the findings suggest that adherence among YPH is relatively good, and that
assessing illness and treatment beliefs may play a valuable role in identifying which individuals
are least likely to adhere to prophylaxis. The findings suggest that interventions aimed at
improving adherence should particularly consider how they may improve social support for
patients, increase patients’ necessity/concern differential scores and positive outcome expecta-
tions. It is also important to consider that negative emotions, such as fear, may for some
patients work as a motivator to keep on track with prophylaxis.
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